The aspirin resistance controversy: clinical entity or platelet heterogeneity?

Circulation. 2006 Jun 27;113(25):2865-7. doi: 10.1161/CIRCULATIONAHA.106.635847.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspirin / pharmacology*
  • Aspirin / therapeutic use
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / prevention & control*
  • Cyclooxygenase 1 / genetics
  • Cyclooxygenase 1 / physiology
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / physiology
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Enzyme Activation / drug effects
  • Female
  • Flow Cytometry
  • Humans
  • Male
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation / genetics
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Function Tests
  • Prevalence
  • Recurrence
  • Thromboxane A2 / blood
  • Time Factors
  • Treatment Refusal

Substances

  • Platelet Aggregation Inhibitors
  • Thromboxane A2
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Aspirin